PRKN
Overview
PRKN (Parkin RBR E3 Ubiquitin Protein Ligase), also known as PARK2, encodes an E3 ubiquitin ligase involved in mitophagy and protein quality control. Originally characterized in familial Parkinson’s disease, PRKN has emerged as a putative tumor suppressor in several cancer types, where its loss via intragenic deletion has been reported.
Alterations observed in the corpus
- Intragenic deletions in 6% (4/65) of triple-negative breast cancers; this represented the first specific association of PRKN with TNBC PMID:22495314
Cancer types (linked)
- Breast cancer (TNBC): recurrent intragenic deletions; first report linking PRKN loss specifically to TNBC PMID:22495314
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data reported in the corpus.
Therapeutic relevance
- No direct therapeutic associations reported in the corpus.
Open questions
- Functional role of PRKN deletion in breast cancer tumorigenesis remains to be characterized; whether loss of mitophagy drives oncogenesis in this context is unresolved.
Sources
This page was processed by entity-page-writer on 2026-05-06.